Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.43 |
| ▸ | LPL | P06858 | 9/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274567 | 0.81 | LIPG (0.43) | LIPGLPLIRAK4DGAT1ABL1 | |
| SCHEMBL19766305 | 0.80 | LIPG (0.47) | LIPGLPLIRAK4DGAT1EGFR | |
| SCHEMBL29412555 | 0.80 | LIPG (0.56) | LIPGLPLIRAK4DGAT1HSD17B1 | |
| SCHEMBL22660881 | 0.80 | LIPG (0.56) | LIPGLPLIRAK4DGAT1HSD17B1 | |
| SCHEMBL17413790 | 0.80 | LPL (0.49) | LIPGLPLIRAK4DGAT1PDGFRB | |
| SCHEMBL29473308 | 0.79 | LIPG (0.50) | LIPGLPLIRAK4DGAT1EGFR | |
| SCHEMBL806784 | 0.78 | LIPG (0.60) | LIPGLPLIRAK4EGFR | |
| SCHEMBL31644025 | 0.77 | LIPG (0.47) | LIPGLPLIRAK4DGAT1PDGFRB | |
| SCHEMBL30919897 | 0.77 | LIPG (0.49) | LIPGLPLDGAT1 | |
| SCHEMBL808246 | 0.77 | LIPG (0.49) | LIPGLPLDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11053241-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2020112937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200172540-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | LIPG 4560/4885LPL 4740/4885IRAK4 30/4885 |
| US-11053241-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | LIPG 4560/4885LPL 4740/4885IRAK4 30/4885 |
| US-20200172540-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | LIPG 4560/4885LPL 4740/4885IRAK4 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.